EMVision Medical Devices (ASX:EMV) said five of the six validation trial sites for its emu bedside brain scanner are actively enrolling and scanning patients, according to a Wednesday Australian bourse filing.
Recruitment is currently ongoing at its third US-based site in New York. The final sixth site for the validation trial recently cleared its local institutional review board.
The validation trial has an estimated enrollment period of six to 12 months, and up to 300 suspected stroke patients will be enrolled across four sites in the US and two sites in Australia.
The firm also secured ethics approval to begin scanning patients with suspected stroke or traumatic brain injury at Princess Alexandra Hospital in Brisbane, Queensland, and John Hunter Hospital in Newcastle, New South Wales. It will use the results for continued device innovation, algorithm enhancement, and data to support indication expansion.
Its shares rose 3% in recent trading on Wednesday.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。